Lessons Learned from Checkpoint Blockade Taraetina PD-1 in Multiple Mveloma

摘要

Immune checkpoints and agonists modulate ongoing, antigen-specific immune responses. Therapeutic blockade of CTLA-4, PD-1, and PD-L1 has proven to be an effective treatment approach for a subset of patients with a variety of cancers of epithelial, mesenchymal, or hematologic origin. In multiple myeloma, a B-cell lymphoid malignanq' of terminally differentiated plasma cells, PD-1 pathway block- ade is ineffective as a single agent. The initial promise in